The phase III VISION trial demonstrated rPFS and OS benefit of 177 Lu-PSMA-617 compared with protocol-permitted standard of care, leading to FDA approval in March 2022. 34 TheraP was a randomized ...

I am a Senior Research Fellow in systematic reviewing at ScHARR, University of Sheffield. I have undertaken numerous evaluations on the clinical effectiveness of a wide range healthcare technologies ...

(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Himisha Beltran discussing when we should assess ...